AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUL 9 - (NewsRx.com & NewsRx.net) -- Both mucosal and systemic vaccination with the Ankara strain of vaccinia virus (MVA) stimulated strong immune responses in mice.
According to a study from Spain and Switzerland, "MVA is a candidate vector for vaccination against pathogens and tumors. Little is known about its behavior in mucosal tissues. We have investigated the fate and biosafety of MVA, when inoculated by different routes in C57BL/6 mice."
"Intranasal inoculation targeted the virus to the nasal associated lymphoid tissue and the lungs, whereas systemic inoculation led to distribution of MVA in almost all lymphoid organs, lungs, and ovaries," reported J. C. Ramirez and collaborators at Centro Nacional de Biotecnologia in Spain and the University of Lausanne in Switzerland. "Intravaginal, intrarectal, and intragastric inoculations failed to induce efficient infection. After 48 hours, no virus was detectable any more in the organs analyzed. Upon intranasal inoculation, no inflammatory reactions were detected in the central nervous system as well as the upper and ...
Source: HighBeam Research, Mucosal and systemic vaccination with vaccinia virus Ankara...